Technical Analysis for SOLTF - Sosei Group Corporation

Grade Last Price % Change Price Change
grade B 23.58 9.93% 2.1300
SOLTF closed up 9.93 percent on Monday, July 29, 2019, on 26 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical SOLTF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Slingshot Bullish Bullish Swing Setup 9.93%
Narrow Range Bar Range Contraction 9.93%
Wide Bands Range Expansion 9.93%
Overbought Stochastic Strength 9.93%
Gapped Down Weakness 9.93%
Gilligan's Island Sell Setup Bearish Swing Setup 9.17%

Older signals for SOLTF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Sosei Group Corporation, a biopharmaceutical company, discovers, develops, and commercializes biopharmaceutical products worldwide. Its marketed products include Seebri/NVA237, an inhaled long-acting muscarinic antagonist indicated as a maintenance bronchodilator treatment for chronic obstructive pulmonary disease (COPD); Ultibro/QVA149, an inhalation capsule for the bronchodilator treatment of COPD; and NorLevo, an oral emergency contraceptive. The company's product pipeline consists of SO-1105, an antifungal agent, which is in Phase III clinical trial for the treatment of oropharyngeal candidiasis in immunocompromised patients; and APP13002 and APP13007, which are in pre-clinical stage for infectious eye diseases, such as cornea and conjunctivitis, and inflammation. It also develops JIT-2001 for cardiovascular disease and JIT-1007 for orphan diseases that are in pre-clinical stage; and discovers and develops pharmaceutical products targeting G protein-coupled receptors. In addition, the company is developing biopharmaceuticals for the treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic diseases, and other indications. The company has a strategic collaboration with PeptiDream Inc. Sosei Group Corporation was founded in 1990 and is headquartered in Tokyo, Japan.
Health Cancer Biopharmaceutical Pharmaceutical Pharmaceutical Products Inflammation Cardiovascular Disease Alzheimer's Disease Chronic Obstructive Pulmonary Disease Metabolic Diseases Respiratory Therapy Biopharmaceuticals Schizophrenia Biopharmaceutical Products Chronic Lower Respiratory Diseases Combination Drugs Migraine Conjunctivitis Orphan Diseases Treatment Of Alzheimer's Disease Copd Pulmonology Muscarinic Antagonists Pulmonary Function Testing
Is SOLTF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 237.05
52 Week Low 8.03
Average Volume 389
200-Day Moving Average 0.0
50-Day Moving Average 16.6385
20-Day Moving Average 16.852
10-Day Moving Average 19.996
Average True Range 1.0912
ADX 26.66
+DI 65.0209
-DI 30.6965
Chandelier Exit (Long, 3 ATRs ) 20.3064
Chandelier Exit (Short, 3 ATRs ) 13.7436
Upper Bollinger Band 23.9433
Lower Bollinger Band 9.7607
Percent B (%b) 0.97
BandWidth 84.159744
MACD Line 0.7365
MACD Signal Line -0.7709
MACD Histogram 1.5075
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.5800
Resistance 3 (R3) 23.5800 23.5800 23.5800
Resistance 2 (R2) 23.5800 23.5800 23.5800 23.5800
Resistance 1 (R1) 23.5800 23.5800 23.5800 23.5800 23.5800
Pivot Point 23.5800 23.5800 23.5800 23.5800 23.5800
Support 1 (S1) 23.5800 23.5800 23.5800 23.5800 23.5800
Support 2 (S2) 23.5800 23.5800 23.5800 23.5800
Support 3 (S3) 23.5800 23.5800 23.5800
Support 4 (S4) 23.5800